OncoMatch/Clinical Trials/NCT07045311
JS207 Combination Therapy in Triple-negative Breast Cancer
Is NCT07045311 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including JS207 in combination with 9MW2821 and JS207 in combination with Albumin paclitaxel for triple-negative breast cancer.
Treatment: JS207 in combination with 9MW2821 · JS207 in combination with Albumin paclitaxel — This is an open-label, multi-center, phase II clinical study to preliminarily evaluate the efficacy and safety of JS207 combined with 9MW2821 or albumin paclitaxel as first-line therapy in patients with recurrent or metastatic TNBC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) wild-type
Required: ESR1 wild-type
Required: PR (PGR) wild-type
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Exception: in (new) adjuvant therapy is allowed, if DFI is ≥6 months
Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or drugs targeting other stimulatory or co-inhibitory T cell receptors (e.g., CTLA-4, OX-40, CD137) in (new) adjuvant therapy is allowed, if DFI is ≥6 months
Cannot have received: antibody-drug conjugate (Enfortumab Vedotin)
previously treated with Antibody-Drug Conjugates conjugated with MMAE and/or targeting Nectin-4, such as Enfortumab Vedotin is not allowed
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify